Holen Sie sich die Stockscreener-App
59.35
1.88%
-1.14
Handel nachbörslich:
59.50
0.15
+0.25%
Schlusskurs vom Vortag:
$60.49
Offen:
$59.34
24-Stunden-Volumen:
3.91M
Relative Volume:
1.75
Marktkapitalisierung:
$9.46B
Einnahmen:
$705.14M
Nettoeinkommen (Verlust:
$-453.90M
KGV:
-19.52
EPS:
-3.04
Netto-Cashflow:
$-551.29M
1W Leistung:
+39.25%
1M Leistung:
+36.59%
6M Leistung:
+80.12%
1J Leistung:
+24.55%
1-Tages-Spanne:
$58.84
$60.75
1-Wochen-Bereich:
$42.13
$62.08
52-Wochen-Spanne:
$23.95
$62.08
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Firmenname
Ionis Pharmaceuticals Inc
Sektor
Branche
Telefon
(760) 931-9200
Adresse
2855 GAZELLE COURT, CARLSBAD, CA
Vergleichen Sie IONS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
59.35 | 9.16B | 705.14M | -453.90M | -551.29M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-31 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-01 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-04-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-08-02 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | Fortgesetzt | Jefferies | Buy |
| 2024-06-14 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-10-23 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Strong Buy |
| 2023-07-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-06-07 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-05-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-03-21 | Eingeleitet | Bernstein | Underperform |
| 2022-12-21 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
| 2022-03-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2022-03-01 | Eingeleitet | Citigroup | Sell |
| 2022-03-01 | Eingeleitet | Guggenheim | Buy |
| 2022-02-01 | Herabstufung | BofA Securities | Buy → Underperform |
| 2021-12-14 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | Hochstufung | UBS | Sell → Neutral |
| 2021-03-01 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2020-12-16 | Eingeleitet | UBS | Sell |
| 2020-12-15 | Hochstufung | Cowen | Market Perform → Outperform |
| 2020-09-14 | Fortgesetzt | JP Morgan | Neutral |
| 2020-09-02 | Eingeleitet | The Benchmark Company | Hold |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Outperform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-12-13 | Eingeleitet | Oppenheimer | Outperform |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | Bestätigt | Stifel | Hold |
| 2018-08-07 | Bestätigt | Stifel | Hold |
| 2018-05-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2017-10-06 | Fortgesetzt | Goldman | Sell |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-08-09 | Bestätigt | Stifel | Hold |
| 2017-03-10 | Herabstufung | Goldman | Neutral → Sell |
| 2016-12-28 | Bestätigt | BMO Capital Markets | Outperform |
| 2016-12-27 | Bestätigt | Leerink Partners | Mkt Perform |
Alle ansehen
Ionis Pharmaceuticals Inc Aktie (IONS) Neueste Nachrichten
Street Watch: Is Ionis Pharmaceuticals Inc. a cyclical or defensive stockJuly 2025 Catalysts & Consistent Profit Trade Alerts - khodrobank.com
Amyotrophic Lateral Sclerosis Pipeline Outlook 2025: Clinical - openPR.com
Ionis Pharmaceuticals Shares Rise After BMO Capital Upgrade - MarketScreener
Key resistance and support levels for Ionis Pharmaceuticals Inc.M&A Rumor & Daily Stock Trend Reports - Newser
What the charts say about Ionis Pharmaceuticals Inc. todayQuarterly Profit Report & Free Weekly Watchlist of Top Performers - Newser
Citigroup maintains Buy rating, raises Ionis Pharmaceuticals PT to $84 from $69. - AInvest
Is Ionis Pharmaceuticals Inc. stock trending bullish2025 Breakouts & Breakdowns & High Accuracy Trade Signal Alerts - khodrobank.com
Ionis Pharma (IONS) Touches New High on Promising Olezarsen Results - MSN
IONS Hits 52-Week High on Tryngolza's Success in Lowering Triglyceride - TradingView
Ionis Pharmaceuticals: BMO Capital Upgrades to Outperform, PT Raised to $70 - AInvest
Market reaction to Ionis Pharmaceuticals Inc.’s recent newsWeekly Trade Review & Long-Term Safe Investment Plans - Newser
Ionis Pharmaceuticals Soars: New Drug Approved - StocksToTrade
Buy IONS Stock After Its 35% Pop? - Trefis
Ionis upgraded at BMO Capital Markets after data for lipid-lowering agent - MSN
Ionis stock upgraded at BMO Capital Markets (IONS:NASDAQ) - Seeking Alpha
Analyzing Ionis Pharmaceuticals Inc. with risk reward ratio charts2025 Major Catalysts & Community Verified Swing Trade Signals - Newser
Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) 34% Share Price Surge Not Quite Adding Up - simplywall.st
Using data filters to optimize entry into Ionis Pharmaceuticals Inc.Buy Signal & Accurate Entry/Exit Alerts - Newser
What’s next for Ionis Pharmaceuticals Inc. stock priceTrade Risk Assessment & Precise Entry and Exit Recommendations - Newser
Ionis Pharmaceuticals Inc. stock prediction for this week2025 Support & Resistance & Low Risk Profit Maximizing Plans - Newser
MSD, Ionis trumpet lipid-lowering drug data - pharmaphorum
BMO Capital Upgrades Ionis Pharmaceuticals to Outperform From Market Perform, Adjusts PT to $70 From $40 - MarketScreener
Will Ionis Pharmaceuticals Inc. bounce back from current supportPortfolio Value Report & Expert Approved Momentum Ideas - Newser
Ionis reports topline outcomes from Phase III trials of olezarsen for sHTG - Yahoo Finance
Ionis Pharmaceuticals shares rise 1.74% premarket after positive Phase 3 study results for olezarsen. - AInvest
Has Ionis Pharmaceuticals Inc. formed a bullish divergenceBuy Signal & Fast Entry Momentum Alerts - Newser
Ionis to present at upcoming September 2025 investor conferences - BioSpace
Comparing Ionis Pharmaceuticals Inc. in custom built stock radarsWeekly Profit Summary & AI Optimized Trade Strategies - Newser
Ionis looks to expand use of lipid-lowering drug after trial hits goal - BioPharma Dive
Narrow-Moat Ionis Expands Its Cardiology and Neurology Portfolio; Positive Long-Term Outlook - Morningstar
Visualizing Ionis Pharmaceuticals Inc. stock with heatmaps2025 Top Gainers & Daily Profit Maximizing Tips - Newser
Ionis reports sHTG win while Arrowhead inks Novartis deal - BioWorld MedTech
IONS Stock Soars: Time to Buy or Stay Cautious? - timothysykes.com
How to use a screener to detect Ionis Pharmaceuticals Inc. breakoutsJuly 2025 Sentiment & Accurate Buy Signal Notifications - Newser
More Ways to Cut Cholesterol, Triglycerides Are Coming. This Stock Took Off. - Barron's
Ionis Looks Set To Own Its First Blockbuster - insights.citeline.com
Ionis to present at upcoming investor conferences - Business Wire
IONS Stock Soars 34% To Hit February 2021 Highs After Medicine Shows Positive Effect On Elevated Triglyceride Levels In Late-Stage Studies - Stocktwits
Ionis Pharmaceuticals: A High-Conviction Buy Amid a Pivotal Data and Launch Timeline in 2025 - AInvest
FDA Greenlights Ionis’ Dawnzera, Shares Soar - StocksToTrade
Ionis shares surge after drug to lower blood fat shows promise in trials - TradingView
Ionis Pharmaceuticals and the Breakthrough Potential of Olezarsen in Severe Hypertriglyceridemia - AInvest
FDA Grants Approval: Ionis Gains Momentum - timothysykes.com
Ionis Pharma Shares Rise After Reporting 'Positive' Olezarsen Data in Severe Hypertriglyceridemia - MarketScreener
Ionis Pharmaceuticals stock rockets 31% to new 52-week high on breakthrough news - TradingView
Real time breakdown of Ionis Pharmaceuticals Inc. stock performancePortfolio Performance Report & Long-Term Investment Growth Plans - Newser
Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday - inkl
Why Is Ionis Pharma Stock Skyrocketing Tuesday?Ionis Pharmaceuticals (NASDAQ:IONS) - Benzinga
Ionis Pharmaceuticals stock holds steady as Stifel maintains $43 target - Investing.com
Ionis Pharmaceuticals stock hits 52-week high at 49.3 USD - Investing.com
Ionis Pharmaceuticals: A High-Conviction Biotech Play Amid Triglyceride-Lowering Breakthroughs and Undervalued Pipeline Potential - AInvest
Finanzdaten der Ionis Pharmaceuticals Inc-Aktie (IONS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):